Summary
Bristol Myers Squibb (BMY) reported its second-quarter results for the period ending June 29, 2018. The company demonstrated continued strong operational performance driven by key products, suggesting a positive trajectory for revenue and profitability. Investors should note the company's ongoing commitment to research and development, which is crucial for its long-term growth prospects and pipeline innovation. The filing indicates a stable financial position, with management focused on strategic execution and navigating the evolving pharmaceutical landscape.
Financial Highlights
58 data pointsBeta
Financial Statements
Beta
| Revenue | $5.70B |
| Cost of Revenue | $1.63B |
| Gross Profit | $4.10B |
| R&D Expenses | $2.44B |
| SG&A Expenses | $1.13B |
| Operating Expenses | $5.19B |
| Interest Expense | $45.00M |
| Net Income | $373.00M |
| EPS (Basic) | $0.23 |
| EPS (Diluted) | $0.23 |
| Shares Outstanding (Basic) | 1.63B |
| Shares Outstanding (Diluted) | 1.64B |
Key Highlights
- 1The report covers the second quarter of 2018, providing a snapshot of the company's performance mid-year.
- 2Financial statements, including Consolidated Statements of Earnings, Comprehensive Income, Balance Sheets, and Cash Flows, are presented.
- 3Management's Discussion and Analysis (MD&A) offers insights into the company's financial condition and operational results.
- 4Disclosure on market risk and controls and procedures are included, providing transparency on business operations.
- 5Information on legal proceedings and risk factors highlights potential challenges and uncertainties.
- 6The filing details unregistered sales of equity securities and the use of proceeds, if any.
- 7Exhibits are listed, which may contain further supporting documentation for the reported period.
Frequently Asked Questions
The 10-Q filing provides detailed financial statements, including the Consolidated Statements of Earnings and Comprehensive Income, which will outline revenue, expenses, and net income for the quarter. Investors should refer to Item 1 of the filing for these specific figures.
Management's Discussion and Analysis (MD&A) in Item 2 is the primary section to understand the drivers of performance. This typically includes commentary on product sales, research and development investments, and any significant operational events impacting results.
Item 1A (Risk Factors) and Item 1 (Legal Proceedings) will detail any significant risks, litigation, or regulatory matters that could impact the company's financial health and future operations.
The Consolidated Balance Sheets and Consolidated Statements of Cash Flows (Item 1) provide the financial position and cash movement details. Reviewing these statements will reveal any material changes in assets, liabilities, equity, or cash generated/used from operating, investing, and financing activities.